ACADIA Hires Todd S. Young
Todd S. Young is now settling into his new role at ACADIA Pharmaceuticals, Inc. as Executive Vice President, Chief Financial Officer. The company perceives his financial and operational experience to be a valuable tool as the company enters a new phase following the launch of Nuplazid.
“His proven finance and leadership skills will be key as we bring Nuplazid to patients in need, seek to maximize the significant opportunities ahead for pimavanserin, and deliver on our vision of building a leading CNS company,” says President and CEO, Steve Davis. “We welcome Todd to our team and look forward to his contributions.”
Most recently, Young served as senior vice president and treasurer at Baxalta Incorporated. Before Baxalta he served multiple roles at Baxter International for 14 years.
Astellas Americas Promotes John Demaree
Astellas Americas named John Demaree as its Vice President, Oncology Marketing. With more than 25 years of experience—20 of which are in oncology—Senior Vice President, Mark Reisenauer, views the promotion as an opportunity for progress and better service to cancer patients. “We are confident that John’s commercial experience in oncology will help us make strides in improving care for the patients we serve,” states Reisenauer.
Demaree will now pilot the Oncology Marketing team for in-market product promotions, new launches, strategic planning and collaborations with partners within the Americas region. He has been with the company since 2011, initially serving as Executive Director, Oncology Marketing, during this time he assisted with the launch of Xtandi.
Announces Jonathan Symonds, CBE, to its Board of Directors. He will serve as an observer and strategic adviser. Symonds previously served as CFO at Novartis AG and also at AstraZeneca plc. He is a recognized independent non-executive Director of HSBC Holdings plc.
Clearside Biomedical Inc.
Appoints Glenn Noronha, PhD, as Chief Scientific Officer. Dr. Noronha has been with the company since 2013 as EVP of Research and Development, chaperoning the company’s scientific affairs and clinical developments. He has over 17 years of experience in clinical and nonclinical research. He will now pilot the strategy and design of all programs.
Announced a newly created position, Chief Growth Officer, who is Eric Steckelman. His responsibilities in the new role include leading client services, business development, and core strategic functions.
Names Chris Mathes, PhD, as Chief Commercial Officer with the intention of amplifying its drug discovery and ion channel service business. Dr. Mathes will manage sales, marketing, and customer relations. Most recently, he served in discovery services at Charles River Laboratories overseeing North American business developments.
Announced its latest hire, Jess Seilheimer as Senior Vice President of Strategic Development. Seilheimer has been assigned to business development, which includes creating operation plans and solutions centered on innovation and digital transformation for existing and future clients.
Names Ernesto Alegria as its Chief Financial Officer. The experienced CFO previously worked at Acino Group, at which one of his key functions included assisting in the organization’s expansion into a mid-size pharmaceutical company. Alegria’s credentials include head of business controlling and finance at Takeda Pharmaceuticals International GmbH, senior financial and commercial roles at Nycomed and Norske Skog.
Announces with great sadness the passing of Chairman and CEO Giovanni Recordati. He became CEO in 1991 and Chairman in 1999. Under his management the company achieved significant growth, gaining international pharmaceutical popularity especially in Europe, North and South America, and North Africa.
Rx EDGE Pharmacy Networks
Appointed Philip Soufleris as Executive Director, Sales. He is expected to aid in all aspects of sales process for the company’s products and services. Soufleris has 30 years of experience in the medical marketing industry. Most recently he served as Vice President, Sales at Frontline Medical Communications.
Spring Bank Pharmaceuticals
Announced Todd C. Brady, MD, PhD, CEO, President, and Director of Aldeyra Therapeutics, as a member of its Board of Directors. Martin Driscoll, Chairman, President, and CEO of Spring Bank anticipates Dr. Brady will be a great asset as the company pursues new endeavors including SB 9200. Driscoll states, “Dr. Brady brings to the Spring Bank Board a wealth of experience across the full spectrum of drug development and biopharmaceutical management.”
Syndax Pharmaceuticals, Inc.
Announces the expansion of its Scientific Advisory Board, to include the company’s Co-founder and SAB Chair, Ronald M. Evans, PhD. Dr. Evans is best recognized for his groundbreaking work on nuclear hormone receptors. His discoveries have led to the development of new drugs for cancer, diabetes, and bone disease. He is also a professor in the gene expression laboratory at the Salk Institute for Biological Studies. The company also named Joseph Paul Eder, MD as part of the board. He is presently Director of the Early Drug Development Program and Assistant Director of Experimental Therapeutics at Yale Cancer Center. Dr. Eder is acknowledged for his drug development and clinical research.
Appoints Michael J. Loiacono as Chief Financial Officer and Chief Accounting Officer. Loiacono has also been entrusted as corporate secretary. He has been with the company since March 2016 as a finance advisor. Loiacono is former CFO of Global Axcess Corporation.
Announced George Golumbeski, PhD, joined the Board of Directors. He brings more than 25 years of executive experience leadership in R&D and business development in the pharma and biotech industries.